Nuvectis Bets on Chinese Approval for Ciprocopan Against Unfavorable European Precedent for Naive PNH

Nuvectis Pharma Secures First Global Approval for Ciprocopan in China

Nuvectis Pharma reported its financial results for the second quarter of 2026 and provided an update on recent business progress. The company completed the in-licensing of ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco Pharmaceutical Group, transforming it into a late-stage clinical development organization. Ciprocopan, a Complement Factor B inhibitor, received its first global marketing approval in China in July 2026 for the treatment of patients with PNH previously untreated with complement inhibitors. Additionally, Nuvectis completed a follow-on offering in July 2026, raising $115 million in gross proceeds, which extends its cash runway into the first half of 2029.

• Nuvectis Pharma has strategically transformed its corporate focus by in-licensing ex-China rights for ciprocopan (NXP100) and NXP200 from Haisco Pharmaceutical Group. This move establishes ciprocopan as the new lead drug candidate and expands the oncology pipeline, positioning Nuvectis as a late-stage clinical development company with a multi-billion-dollar market potential.
• Ciprocopan (NXP100), a once-daily, oral Complement Factor B inhibitor, achieved its first global marketing approval in China in July 2026. This approval is for patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not been previously treated with complement inhibitors, highlighting its compelling clinical profile and validating its therapeutic potential for complement-mediated diseases.
• The company significantly strengthened its financial position by completing a follow-on public offering in July 2026, which generated $115 million in gross proceeds. This successful transaction, anchored by leading healthcare investors, extends Nuvectis' cash runway into the first half of 2029, providing crucial resources to advance ciprocopan's development and execute its broader oncology portfolio strategy.

Addressing Unmet Needs in PNH: The Rationale for Ciprocopan

Despite significant advances in complement-targeted therapy, current treatment approaches for paroxysmal nocturnal hemoglobinuria (PNH) leave substantial unmet needs across efficacy, accessibility, and patient burden. These limitations span traditional supportive care, transplantation, and even the most advanced anti-complement biologics, underscoring the rationale for continued innovation in this space.

• Incomplete hemolysis control with C5 inhibitors: Eculizumab and ravulizumab effectively address intravascular hemolysis but fail to prevent complement C3-mediated extravascular hemolysis, which develops in most treated patients and contributes to residual anemia and suboptimal quality-of-life improvement. In head-to-head data, only 15% of eculizumab-treated patients achieved transfusion independence versus 85% with pegcetacoplan, and breakthrough hemolysis occurred in 23% of eculizumab patients versus 10% with pegcetacoplan.

• Genetic resistance and breakthrough events: Primary resistance driven by C5 gene polymorphisms—identified as three distinct mutations most prevalent in Japanese, Korean, and African populations—renders some patients unresponsive to eculizumab despite therapy. Complement-amplifying conditions such as infection or vaccination can further trigger acute breakthrough hemolysis in roughly half of patients.

• Treatment burden and administration challenges: Eculizumab requires intravenous infusion weekly for five weeks followed by biweekly dosing thereafter, limiting patient convenience and independence. Broader access barriers compound this burden, including long travel distances (averaging 87.5 km in Brazil), extended waiting times, and a mean time to treatment initiation of 172.9 days; non-persistence rates ranged from 21.2% to 61.0% depending on methodology.

• Infectious and safety risks: Eculizumab carries risk of serious infections, including Neisseria meningitidis, Neisseria gonorrhoeae, unusual Neisseria species, Moraxella lacunata, and Pseudomonas aeruginosa, with potential for septic shock and mortality.

• Limitations of transplantation and traditional supportive care: Allogeneic stem cell transplantation remains the only potentially curative option for severe aplasia but carries high morbidity and mortality; in one cohort, 3 of 13 HSCT patients died from graft-versus-host disease. Traditional supportive therapies (transfusions, anticoagulation, iron/folate supplementation) remain largely empirical and symptomatic, failing to prevent critical complications such as thrombosis and chronic kidney disease.

• Disease heterogeneity and diagnostic delay: Management is complicated by PNH's close association with bone marrow failure syndromes, requiring differentiated approaches for classic PNH, PNH with underlying marrow failure, and subclinical disease. Median time to diagnosis has been reported at 30 months, and in earlier alternative-therapy cohorts, 16% of patients died from thrombosis or hemorrhage within 3 months of treatment initiation before response could even be assessed.

• Cost-effectiveness and long-term safety uncertainty: Eculizumab has been shown to be not cost-effective compared with other disease-modifying therapies or standard of care, raising questions about sustainable access. Long-term safety and patient compliance with newer oral and subcutaneous proximal complement inhibitors also require further investigation as these agents move into broader clinical use.

The Competitive Landscape for Oral Complement Factor B Inhibitors in PNH

Iptacopan, an oral, selective complement factor B inhibitor, is a key emerging therapy for paroxysmal nocturnal hemoglobinuria (PNH). Based on the available literature, no other factor B inhibitors were identified as being in trials for PNH, establishing iptacopan's unique position within this specific mechanism of action. However, the broader competitive landscape for PNH includes several other approved complement inhibitors that target different components of the complement cascade.